Trial No. IPR2013-00187 Docket No.: 0100678-00140

Filed on behalf of Atrium Medical Corporation
By: David L. Cavanaugh, Reg. No. 36,476
Larissa Park, Reg. No. 59,051
Wilmer Cutler Pickering Hale and Dorr LLP
1875 Pennsylvania Ave., NW
Washington, DC 20006

Tel: (202) 663-6025

Email: David.Cavanaugh@wilmerhale.com Larissa.Park@wilmerhale.com

## UNITED STATES PATENT AND TRADEMARK OFFICE

\_\_\_\_\_

## BEFORE THE PATENT TRIAL AND APPEAL BOARD

\_\_\_\_\_

### ATRIUM MEDICAL CORPORATION

Petitioner

V.

DAVOL, INC.

Patent Owner of U.S. Patent No. 7,785,334 to Ford et al.

IPR Trial No. IPR2013-00187

## **DECLARATION OF THEODORE KARWOSKI**

Atrium v. Davol IPR2013-00187 ATRIUM 1129





- I, Theodore Karwoski, declare as follows:
- 1. My name is Theodore Karwoski.
- 2. From 1982 through 2013, I worked at Atrium Medical Corporation ("Atrium"), serving variously as Chief Operating Officer, Chief Development Officer, and Senior Vice President of Research and Operations. I am now a consultant to Atrium.
- 3. Atrium is in the business of making and selling medical devices, including hernia repair devices such as plugs and patches. In the late 1990s, Atrium introduced its Self-Forming Plug, a hernia repair device with three layers of polypropylene mesh including a tissue barrier layer and a center rectangular tab for placement, control of insertion, positioning and attachment. Patented by Atrium in 2000, the Self-Forming Plug was designed to expand into and conform to the shape and space of a hernia defect. Atrium still sells it today.
- 4. In 2006, Atrium received FDA clearance for, and began to market, its C-QUR<sup>TM</sup> Mesh, a hernia repair device consisting of Atrium's polypropylene mesh coated with Omega-3 fatty acid ("O3FA"). The C-QUR<sup>TM</sup> Mesh was designed to be a tissue separating layer for open and laparoscopic hernia repair. Atrium still sells it today.



- 5. In late 2005, Atrium began development of the C-QUR V-Patch<sup>TM</sup> ("V-Patch<sup>TM</sup>"). In 2008, Atrium received FDA clearance for, and began to market, the device. Atrium's V-Patch<sup>TM</sup> is designed to repair small hernias and other abdominal wall defects. It has an O3FA bioabsorbable coating and is constructed out of two layers of polypropylene mesh that are sewn with, and include, a mesh stabilizing ring. The O3FA bioabsorbable coating is integral to the polypropylene mesh. Building off the success of Atrium's Self-Forming Plug's prior art tabs, it also has two extended mesh fixation straps to allow the doctor to position, fixate, and handle the patch.
- 6. Both patents in these proceedings issued *after* the V-Patch<sup>TM</sup> was approved for clearance in 2008: the '334 Patent issued on August 31, 2010 and the '905 Patent issued on October 5, 2010.
- 7. Davol, Inc. ("Davol") competes with Atrium in the hernia repair device market. Since 2002, Davol or its parent company, C.R. Bard, Inc. ("Bard"), have marketed and sold the Ventralex<sup>TM</sup> patch.
- 8. I understand that, in this proceeding, Davol employee Michael Lee has testified that Atrium copied Davol's Ventralex<sup>TM</sup> patch. Specifically, I understand that Mr. Lee claims that Atrium's V-Patch<sup>TM</sup> is a copy of Davol's Ventralex<sup>TM</sup> patch.



- 9. Atrium did not copy Davol's Ventralex<sup>TM</sup> patch, and Atrium's V-Patch<sup>TM</sup> is not a copy of Davol's Ventralex<sup>TM</sup> patch.
- As a medical device manufacturer, Atrium naturally wants to develop 10. and sell superior products to compete in the marketplace. In response to requests from doctors for a hernia repair device that would perform better than competitors' products (such as Davol's Ventralex<sup>TM</sup> patch), Atrium developed the V-Patch<sup>TM</sup>. Beginning in the early 1990s, various plugs and patches were developed to improve repairs made in abdominal wall defects. These implants evolved based upon surgical use and surgeons' feedback on improvements in techniques and design. Initial plugs were found to migrate after insertion due to inadequate anchoring and abdominal wall defect increases and changes, to harden due to poor tissue integration, and to have other inadequacies. Atrium's Self-Forming Plug as marketed (in 1997) and patented (in 2000) built upon prior art evolution and improvements. Through surgical use, Surgeons soon recognized that they could modify the circular plug with tabs of Atrium's Self-Forming Plug to provide a patch, or shield, covering a defect through the abdominal wall. Surgeons then suggested modifications to the Self-Forming Plug's design, and those suggestions were part of the variety of product evolutions and designs that led to the V-Patch<sup>TM</sup> product.



- 11. Atrium's V-Patch<sup>TM</sup> and Davol's Ventralex<sup>TM</sup> patch share certain features, such as a multiple layer structure, use of polypropylene mesh, use of a barrier, and straps. All of these features, however, were well-known in the pre-2002 prior art. None is unique to Atrium or Davol's products.
- 12. Unlike Atrium's V-Patch<sup>TM</sup>, however, Davol's Ventralex<sup>TM</sup> patch has *no* O3FA coating. The Atrium V-Patch<sup>TM</sup>'s O3FA coating has been shown to minimize visceral tissue attachment to the mesh, and was designed in response to doctors' demands for a better-performing product.
- 13. Both Atrium's V-Patch<sup>TM</sup> and Davol's Ventralex<sup>TM</sup> patch come in identical sizes. That similarity, however, is due not to copying but rather to doctors' preferences and the limited range of sizes for the products' shared purpose (the repair of small hernia-related defects).

## **Availability for Cross-Examination**

14. In signing this declaration, I recognize that the declaration will be filed as evidence in a contested case before the Patent Trial and Appeal Board of the United States Patent and Trademark Office. I also recognize that I may be subject to cross examination in the case and that cross examination will take place within the United States. If cross examination is required of me, I will appear for cross examination within the United States during the time allotted for cross examination.



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

